PUBLISHER: Renub Research | PRODUCT CODE: 1463196
PUBLISHER: Renub Research | PRODUCT CODE: 1463196
Anti-Venom Market Report by Type (Polyvalent Anti-Venom and Monovalent Anti-Venom), Animal Type (Wheat Snake, Scorpion, Spider, and Others), End User (Clinics, Hospitals, Ambulatory Surgical Centers, and Others), Region and Company Analysis 2024-2032
Global anti-venom market is expected to reach a value of US$ 1.95 Billion by 2032, with a projected CAGR of 6.46% between 2024 and 2032. The market was valued at US$ 1.11 Billion in 2023.
Anti-venoms consist of antibodies used to treat venomous stings or bites. The growing prevalence of snake and other animal bites, such as fish stings, drives the anti-venom market.The global market for anti-venom is expected to grow due to increasing investment in developing new drugs and technological innovation in treating venomous bites. The growing incidence of snakebites worldwide is another major factor contributing to market growth. According to the World Health Organization (WHO), around 5.4 million people are bitten by snakes a year, resulting in a high demand for anti-venoms. However, the production of anti-venoms faces regulatory challenges in several countries.
Antivenom Market Data and Statistics
- The WHO has launched a strategy to prevent and control snakebite envenoming, a tropical disease affecting millions annually.
- Snakebites are a significant issue worldwide. In Asia, about 2 million individuals suffer from snakebites each year, while in Africa, an estimated 435,000 to 580,000 people require treatment for snakebites annually.
- India alone has 2.8 million snakebite cases, with 46,900 deaths every year.
- A study from the National Center for Biotechnology Information (NCBI) found that a snakebite treatment ward in a Bangladesh tertiary hospital experienced a 25% decrease in overall snakebite hospital admissions in 2020 compared to previous years.
- Ten laboratories in Latin America, including Instituto Nacional de Salud and Instituto Butantan, have observed a decline in snake antivenom production in 2021.
- According to Centers for Medicare & Medicaid Services (CMS), National Health Expenditures (NHE) in the US are projected to reach USD 6,192.5 Billion in 2028 with an average annual percent change of 5.2%.
- The per capita expenditure is estimated to touch USD 17,611 by 2028, implying that this growth in NHE is expected to create lucrative business opportunities.
United States Anti Venom Market
The anti venom market in the U.S. is expected to have significant growth due to the country's high occurrence of snake bites. The market's expansion is expected to be driven by announcements from considerable market players, such as the Fast Track designation granted by the US FDA to Ophirex'sdarapladib-methyl for the treatment of snakebite, and the approval received by Rare Disease Therapeutics, Inc. for ANAVIP. ANAVIP is approved for managing adult and pediatric patients with pit viper envenomation in the United States of America, and these announcements are expected to contribute to the market's growth.
India Anti Venom Market
India is home to almost 275 species of snakes, out of which only 60 are venomous and considered medically relevant, with four having significant mortality and morbidity. These four venomous snakes are collectively called the "Big Four." Anti-venom is a biological product that detoxifies the poisoning of venomous bites. Venomous bites can result in various clinical conditions, and it is estimated that around 40,000-80,000 people die in Asia, mainly in India, from snakebites annually. Antivenom products have been developed to counter the poisonous effects of venomous bites, including vaccines and hyperimmune sera.
Global Anti Venom Market Company Analysis
The companies that make up the global anti-venom market include Bharat Serums and Vaccines Limited (BSV), Boehringer Ingelheim International GmbH, Boston Scientific Corporation, CSL Limited, Merck & Co. Inc., Merck KGaA, Pfizer Inc., and Haffkine Bio-Pharmaceutical Corporation Limited.
Global Anti Venom Market Company News
In July 2022, the AVRDC foundation was laid at IBAB, Bengaluru Helix Biotech Park, Electronics City, to boost antivenom production.
In April 2022, Brazil and the government of Myanmar signed a complementary agreement to improve the quality and performance of anti venom serum produced in Myanmar. The project is "Improving methodologies and techniques for the production of anti venom serum in Myanmar-phase II: anti venom quality."
BSV and IISc collaborated in August 2022 to develop antivenom for snakebites in India, addressing the unique challenges specific to the region.
Ophirex, Inc. received Fast Track Designation from the U.S. FDA in March 2022 for darapladib-methyl, a treatment for snakebite. The FDA recognized the drug's potential benefits and the need to bring it to market efficiently.
Rare Disease Therapeutics, Inc. expanded FDA approval for the ANAVIP antivenom to treat North American Pit Viper Envenomation in April 2021, indicating progress in developing effective snakebite therapies.
Type - Global Anti-Venom Market breakup in 2 viewpoints:
1. Polyvalent Anti-Venom
2. Monovalent Anti-Venom
Animal Type - Global Anti-Venom Market breakup in 4 viewpoints:
1. WheatSnake
2. Scorpion
3. Spider
4. Others
End-User - Global Anti-Venom Market breakup in 4 viewpoints:
1. WheatClinics
2. Hospitals
3. Ambulatory Surgical Centers
4. Others
Country - Global Anti-Venom Market breakup of 25 Countries:
1. North America
- 1.1 United States
- 1.2 Canada
2. Europe
- 2.1 France
- 2.2 Germany
- 2.3 Italy
- 2.4 Spain
- 2.5 United Kingdom
- 2.6 Belgium
- 2.7 Netherlands
- 2.8 Turkey
3. Asia Pacific
- 3.1 China
- 3.2 Japan
- 3.3 India
- 3.4 South Korea
- 3.5 Thailand
- 3.6 Malaysia
- 3.7 Indonesia
- 3.8 Australia
- 3.9 New Zealand
4. Latin America
- 4.1 Brazil
- 4.2 Mexico
- 4.3 Argentina
5. Middle East & Africa
- 5.1 Saudi Arabia
- 5.2 UAE
- 5.3 South Africa
All the Key players have been covered from 3 Viewpoints:
- Overview
- Recent Development
- Revenue Analysis
Company Analysis:
1. Bharat Serums and Vaccines Limited (BSV)
2. Boehringer Ingelheim International GmbH
3. Boston Scientific Corporation
4. CSL Limited
5. Merck & Co. Inc.
6. Merck KGaA
7. Pfizer Inc.
8. Haffkine Bio-Pharmaceutical Corporation Limited
Table of Contents
1. Introduction
2. Research& Methodology
3. Executive Summary
4. Market Dynamics
- 4.1 Growth Drivers
- 4.2 Challenges
5. Global Anti-Venom Market
6. Market Share - Global Anti-Venom Analysis
- 6.1 Type
- 6.2 Animal Type
- 6.3 End Users
- 6.4 Country
7. Type - Global Anti-Venom Market
- 7.1 Polyvalent Anti-Venom
- 7.2 Monovalent Anti-Venom
8. Animal Type - Global Anti-Venom Market
- 8.1 Snake
- 8.2 Scorpion
- 8.3 Spider
- 8.4 Others
9. End Users - Global Anti-Venom Market
- 9.1 Clinics
- 9.2 Hospitals
- 9.3 Ambulatory Surgical Centers
- 9.4 Others
10. Country - Global Anti-Venom Market
- 10.1 North America
- 10.1.1 United States
- 10.1.2 Canada
- 10.2 Europe
- 10.2.1 France
- 10.2.2 Germany
- 10.2.3 Italy
- 10.2.4 Spain
- 10.2.5 United Kingdom
- 10.2.6 Belgium
- 10.2.7 Netherlands
- 10.2.8 Turkey
- 10.3 Asia Pacific
- 10.3.1 China
- 10.3.2 Japan
- 10.3.3 India
- 10.3.4 South Korea
- 10.3.5 Thailand
- 10.3.6 Malaysia
- 10.3.7 Indonesia
- 10.3.8 Australia
- 10.3.9 New Zealand
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.2 Mexico
- 10.4.3 Argentina
- 10.5 Middle East & Africa
- 10.5.1 Saudi Arabia
- 10.5.2 UAE
- 10.5.3 South Africa
11. Porter's Five Analysis - Global Anti-Venom Market
- 11.1 Bargaining Power of Buyers
- 11.2 Bargaining Power of Suppliers
- 11.3 Degree of Rivalry
- 11.4 Threat of New Entrants
- 11.5 Threat of Substitutes
12. SWOT Analysis - Global Anti-Venom Market
- 12.1 Strength
- 12.2 Weakness
- 12.3 Opportunity
- 12.4 Threat
13. Key Players
- 13.1 Bharat Serums and Vaccines Limited (BSV)
- 13.1.1 Overview
- 13.1.2 Recent Development
- 13.1.3 Revenue
- 13.2 Boehringer Ingelheim International GmbH
- 13.2.1 Overview
- 13.2.2 Recent Development
- 13.2.3 Revenue
- 13.3 Boston Scientific Corporation
- 13.3.1 Overview
- 13.3.2 Recent Development
- 13.3.3 Revenue
- 13.4 CSL Limited
- 13.4.1 Overview
- 13.4.2 Recent Development
- 13.4.3 Revenue
- 13.5 Merck & Co. Inc.
- 13.5.1 Overview
- 13.5.2 Recent Development
- 13.5.3 Revenue
- 13.6 Merck KGaA
- 13.6.1 Overview
- 13.6.2 Recent Development
- 13.6.3 Revenue
- 13.7 Pfizer Inc.
- 13.7.1 Overview
- 13.7.2 Recent Development
- 13.7.3 Revenue
- 13.8 Haffkine Bio-Pharmaceutical Corporation Limited
- 13.8.1 Overview
- 13.8.2 Recent Development
List of Figures
- Figure-01: Global - Anti-Venom Market (Billion US$), 2019 - 2023
- Figure-02: Global - Forecast for Anti-Venom Market (Billion US$), 2024 - 2032
- Figure-03: Type - Polyvalent Anti-Venom Market (Million US$), 2019 - 2023
- Figure-04: Type - Forecast for Polyvalent Anti-Venom Market (Million US$), 2024 - 2032
- Figure-05: Type - Monovalent Anti-Venom Market (Million US$), 2019 - 2023
- Figure-06: Type - Forecast for Monovalent Anti-Venom Market (Million US$), 2024 - 2032
- Figure-07: Animal Type - Snake Market (Million US$), 2019 - 2023
- Figure-08: Animal Type - Forecast for Snake Market (Million US$), 2024 - 2032
- Figure-09: Animal Type - Scorpion Market (Million US$), 2019 - 2023
- Figure-10: Animal Type - Forecast for Scorpion Market (Million US$), 2024 - 2032
- Figure-11: Animal Type - Spider Market (Million US$), 2019 - 2023
- Figure-12: Animal Type - Forecast for Spider Market (Million US$), 2024 - 2032
- Figure-13: Animal Type - Others Market (Million US$), 2019 - 2023
- Figure-14: Animal Type - Forecast for Others Market (Million US$), 2024 - 2032
- Figure-15: End Users - Clinics Market (Million US$), 2019 - 2023
- Figure-16: End Users - Forecast for Clinics Market (Million US$), 2024 - 2032
- Figure-17: End Users - Hospitals Market (Million US$), 2019 - 2023
- Figure-18: End Users - Forecast for Hospitals Market (Million US$), 2024 - 2032
- Figure-19: End Users - Ambulatory Surgical Centers Market (Million US$), 2019 - 2023
- Figure-20: End Users - Forecast for Ambulatory Surgical Centers Market (Million US$), 2024 - 2032
- Figure-21: End Users - Others Market (Million US$), 2019 - 2023
- Figure-22: End Users - Forecast for Others Market (Million US$), 2024 - 2032
- Figure-23: United States - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-24: United States - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-25: Canada - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-26: Canada - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-27: France - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-28: France - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-29: Germany - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-30: Germany - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-31: Italy - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-32: Italy - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-33: Spain - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-34: Spain - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-35: United Kingdom - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-36: United Kingdom - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-37: Belgium - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-38: Belgium - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-39: Netherlands - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-40: Netherlands - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-41: Turkey - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-42: Turkey - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-43: China - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-44: China - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-45: Japan - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-46: Japan - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-47: India - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-48: India - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-49: South Korea - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-50: South Korea - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-51: Thailand - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-52: Thailand - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-53: Malaysia - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-54: Malaysia - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-55: Indonesia - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-56: Indonesia - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-57: Australia - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-58: Australia - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-59: New Zealand - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-60: New Zealand - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-61: Brazil - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-62: Brazil - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-63: Mexico - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-64: Mexico - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-65: Argentina - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-66: Argentina - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-67: Saudi Arabia - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-68: Saudi Arabia - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-69: UAE - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-70: UAE - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-71: South Africa - Anti-Venom Market (Million US$), 2019 - 2023
- Figure-72: South Africa - Forecast for Anti-Venom Market (Million US$), 2024 - 2032
- Figure-73: Bharat Serums and Vaccines Limited (BSV) - Global Revenue Market (Million US$), 2019 - 2023
- Figure-74: Bharat Serums and Vaccines Limited (BSV) - Forecast for Global Revenue Market (Million US$), 2024 - 2032
- Figure-75: Boehringer Ingelheim International GmbH - Global Revenue Market (Million US$), 2019 - 2023
- Figure-76: Boehringer Ingelheim International GmbH - Forecast for Global Revenue Market (Million US$), 2024 - 2032
- Figure-77: Boston Scientific Corporation - Global Revenue Market (Million US$), 2019 - 2023
- Figure-78: Boston Scientific Corporation - Forecast for Global Revenue Market (Million US$), 2024 - 2032
- Figure-79: CSL Limited - Global Revenue Market (Million US$), 2019 - 2023
- Figure-80: CSL Limited - Forecast for Global Revenue Market (Million US$), 2024 - 2032
- Figure-81: Merck & Co. Inc. - Global Revenue Market (Million US$), 2019 - 2023
- Figure-82: Merck & Co. Inc. - Forecast for Global Revenue Market (Million US$), 2024 - 2032
- Figure-83: Merck KGaA - Global Revenue Market (Million US$), 2019 - 2023
- Figure-84: Merck KGaA - Forecast for Global Revenue Market (Million US$), 2024 - 2032
- Figure-85: Pfizer Inc. - Global Revenue Market (Million US$), 2019 - 2023
- Figure-86: Pfizer Inc. - Forecast for Global Revenue Market (Million US$), 2024 - 2032
List of Tables
- Table-01: Global - Anti-Venom Market Share by Type (Percent), 2019 - 2023
- Table-02: Global - Forecast for Anti-Venom Market Share by Type (Percent), 2024 - 2032
- Table-03: Global - Anti-Venom Market Share by Animal Type (Percent), 2019 - 2023
- Table-04: Global - Forecast for Anti-Venom Market Share by Animal Type (Percent), 2024 - 2032
- Table-05: Global - Anti-Venom Market Share by End User (Percent), 2019 - 2023
- Table-06: Global - Forecast for Anti-Venom Market Share by End User (Percent), 2024 - 2032
- Table-07: Global - Anti-Venom Market Share by Countries (Percent), 2019 - 2023
- Table-08: Global - Forecast for Anti-Venom Market Share by Countries (Percent), 2024 - 2032
